Financial Times US Pharma and Biotech Summit 2025

The Financial Times US Pharma and Biotech Summit 2025 is a major event dedicated to the biopharmaceutical industry.

Organized by FT Live in collaboration with Endpoints News, the US Pharma and Biotech Summit 2025 brings together top managers, executives, investors and experts from life science communities.

Novalix, Strategic Partner at the US Pharma and Biotech Summit 2025

Be part of exclusive onstage discussions alongside key speakers:

– Stephan Jenn, President, Novalix
– Falko Busse, President, Bruker BioSpin
– Chris Boerner, CEO, Bristol Myers Squibb
– Joe Betts-LaCroix, CEO, Retro Biosciences
– Senior executives from Biogen, Takeda, Regeneron, and Novo Nordisk

Cracking pharma’s R&D conundrum: Achieving effective AI integration

From 2:30 PM to 2:50 PM (EDT) / 8:30 PM – 8:50 PM (local time)
Do not miss the 20′ talk with Stephan Jenn and Falko Busse on AI integration in pharma’s research and development. Join the discussion about how Bruker, the industry leading instrument maker and Novalix, an early-stage drug discovery company, are establishing the lab of the Augmented Scientist to tackle profound challenges in early-stage drug discovery and enhance productivity. 
Register here to secure your entry:

Innovating and investing in a new era for American healthcare

Some key themes include discussions on:

– Trump 2.0 and biopharma
– Dealmaking environment
– Clinical trial agility
– AI in life sciences
– Advanced therapies
– Biopharma workforce transformation

As a key player in drug discovery innovation, we are excited to connect with industry leaders, share insights, and explore new opportunities that will shape the future of pharma and biotech.
Stay tuned for more details on our participation and see you at the Summit!